Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
2011
Stability of BRAF V600E mutation in metastatic melanoma
Sample size: 34
publication
Evidence: moderate
Author Information
Author(s): Sigalotti L, Fratta E, Parisi G, Coral S, Maio M
Primary Institution: Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico
Hypothesis
Does the BRAF mutational status evolve with disease progression in metastatic melanoma?
Conclusion
The BRAF V600E mutational status remains largely unchanged in subsequent melanoma metastases once the disease has reached the metastatic stage.
Supporting Evidence
- 10 out of 15 patients retained the original heterozygous BRAFV600E status.
- 2 out of 15 patients acquired a homozygous mutated status.
- No BRAFV600E mutation was acquired in three patients with an initial homozygous wild-type BRAF genotype.
- Single-cell clones retained the genotypes of the parental metastatic cells.
Takeaway
When melanoma spreads, the BRAF mutation stays pretty much the same, which helps doctors know how to treat it better.
Methodology
Investigated the BRAFV600E mutation in primary cell cultures from metastatic lesions of melanoma patients.
Participant Demographics
15 cutaneous melanoma patients with metastatic lesions.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website